TR201909647T4 - Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car). - Google Patents

Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car). Download PDF

Info

Publication number
TR201909647T4
TR201909647T4 TR2019/09647T TR201909647T TR201909647T4 TR 201909647 T4 TR201909647 T4 TR 201909647T4 TR 2019/09647 T TR2019/09647 T TR 2019/09647T TR 201909647 T TR201909647 T TR 201909647T TR 201909647 T4 TR201909647 T4 TR 201909647T4
Authority
TR
Turkey
Prior art keywords
car
cells
cell
seq
cat19
Prior art date
Application number
TR2019/09647T
Other languages
English (en)
Turkish (tr)
Inventor
PULÉ Martin
Mekkaoui Leila
Amrolia Persis
Ghorashian Sara
Kramer Anne
Cheung Gordon
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of TR201909647T4 publication Critical patent/TR201909647T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
TR2019/09647T 2015-03-05 2016-03-04 Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car). TR201909647T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201503742A GB201503742D0 (en) 2015-03-05 2015-03-05 Chimeric antigen receptor

Publications (1)

Publication Number Publication Date
TR201909647T4 true TR201909647T4 (tr) 2019-07-22

Family

ID=52998440

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09647T TR201909647T4 (tr) 2015-03-05 2016-03-04 Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car).

Country Status (15)

Country Link
US (3) US10457730B2 (cg-RX-API-DMAC7.html)
EP (1) EP3265490B1 (cg-RX-API-DMAC7.html)
JP (1) JP6574848B2 (cg-RX-API-DMAC7.html)
CN (1) CN107406517B (cg-RX-API-DMAC7.html)
AU (1) AU2016227498B2 (cg-RX-API-DMAC7.html)
CA (1) CA2978381C (cg-RX-API-DMAC7.html)
DK (1) DK3265490T3 (cg-RX-API-DMAC7.html)
ES (1) ES2732067T3 (cg-RX-API-DMAC7.html)
FR (1) FR25C1040I1 (cg-RX-API-DMAC7.html)
GB (1) GB201503742D0 (cg-RX-API-DMAC7.html)
HU (2) HUE044298T2 (cg-RX-API-DMAC7.html)
PL (1) PL3265490T3 (cg-RX-API-DMAC7.html)
PT (1) PT3265490T (cg-RX-API-DMAC7.html)
TR (1) TR201909647T4 (cg-RX-API-DMAC7.html)
WO (1) WO2016139487A1 (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102508166B1 (ko) 2014-04-10 2023-03-13 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 세포 면역요법을 위한 방법 및 조성물
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
IL274903B (en) 2014-12-24 2022-07-01 Ucl Business Ltd A cell that simultaneously expresses a chimeric antigen receptor (car) of 19cd and 22cd
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
US9681109B2 (en) * 2015-08-20 2017-06-13 Qualcomm Incorporated Systems and methods for configurable demodulation
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
CN117384929A (zh) 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
CN107098981B (zh) * 2017-06-29 2020-05-01 青岛麦迪赛斯医疗技术有限公司 一种靶向cd19的嵌合抗原受体修饰的t淋巴细胞
CA3071495A1 (en) * 2017-08-02 2019-02-07 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
EP3722313A4 (en) * 2017-12-06 2021-02-24 AbClon Inc. ANTIBODY OR ITS BINDING FRAGMENT TO THE ANTIGEN TO SPECIFICALLY RECOGNIZE A B-CELL MALIGNITY, CHEMERIC ANTIGEN RECEPTOR INCLUDING IT, AND ITS USE
CN107903326B (zh) * 2018-01-02 2020-06-30 广东省人民医院(广东省医学科学院) 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019154313A1 (zh) * 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
CN110372796B (zh) * 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
EP3794034A1 (en) 2018-05-15 2021-03-24 Autolus Limited Chimeric antigen receptor
CN108794642A (zh) * 2018-07-05 2018-11-13 宁波安诺柏德生物医药科技有限公司 一种嵌合抗原细胞受体及其应用
CN110819678A (zh) * 2018-08-07 2020-02-21 上海恒润达生生物科技有限公司 一种评估cart细胞有效性的方法
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3113896A1 (en) 2018-09-27 2020-04-02 Autolus Limited Chimeric antigen receptor
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
CN109468282B (zh) * 2018-11-22 2019-06-18 青岛协和华美医学诊断技术有限公司 一种靶向cd19的嵌合抗原受体t细胞的制备方法及应用
CN109734813B (zh) * 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
EP3912992A4 (en) * 2019-02-04 2022-11-23 National University Corporation Ehime University Car library and production method for scfv
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
CA3130103A1 (en) 2019-02-13 2020-08-20 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
JP7629414B2 (ja) * 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ
AU2020298572A1 (en) 2019-07-02 2021-11-18 Fred Hutchinson Cancer Center Recombinant Ad35 vectors and related gene therapy improvements
CN114286683B (zh) * 2019-07-17 2024-10-01 新加坡国立大学 由免疫细胞合成和分泌的功能性结合物
US20220298223A1 (en) * 2019-08-28 2022-09-22 King's College London B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS
CN115279381A (zh) * 2020-01-13 2022-11-01 恩卡尔塔公司 Bcma定向性细胞免疫疗法组合物和方法
JP2023517011A (ja) 2020-03-05 2023-04-21 ネオティーエックス セラピューティクス リミテッド 免疫細胞を用いて癌を治療するための方法および組成物
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
CN115551893A (zh) * 2020-05-08 2022-12-30 西雅图儿童医院以西雅图儿童研究机构名义经营 靶向自然杀伤细胞的嵌合抗原受体(car)
WO2022031597A1 (en) 2020-08-03 2022-02-10 Kyverna Therapeutics, Inc. Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
WO2022072515A1 (en) * 2020-09-29 2022-04-07 Washington University Methods to determine risk of neurotoxicity
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
US20240316199A1 (en) 2020-12-30 2024-09-26 Alaunos Therapeutics, Inc. Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
JP2024527180A (ja) * 2021-04-08 2024-07-22 クレージュ メディカル カンパニー，リミテッド 細胞免疫療法の使用
CN117088975B (zh) * 2022-05-11 2024-06-25 东莞市朋志生物科技有限公司 抗白蛋白抗体、检测白蛋白的试剂和试剂盒
WO2023218381A1 (en) 2022-05-11 2023-11-16 Autolus Limited Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
CN116253794B (zh) * 2022-08-19 2025-04-04 首都医科大学宣武医院 一种用于car-t细胞调控的抗体及其应用
EP4626447A1 (en) 2023-03-31 2025-10-08 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
WO2024246526A1 (en) 2023-05-30 2024-12-05 Autolus Limited Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
WO2025008642A1 (en) 2023-07-05 2025-01-09 Autolus Limited Method
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
GB202316184D0 (en) 2023-10-23 2023-12-06 Autolus Ltd Method
WO2025088308A1 (en) 2023-10-23 2025-05-01 Autolus Limited Products and methods for treating autoimmune diseases
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025215360A1 (en) 2024-04-09 2025-10-16 Autolus Limited Method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2753158A1 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
CA2863799C (en) * 2012-02-22 2020-09-01 Matthew J. FRIGAULT Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP3546572B9 (en) * 2013-05-13 2024-06-26 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
IL274903B (en) 2014-12-24 2022-07-01 Ucl Business Ltd A cell that simultaneously expresses a chimeric antigen receptor (car) of 19cd and 22cd
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor

Also Published As

Publication number Publication date
WO2016139487A1 (en) 2016-09-09
EP3265490B1 (en) 2019-05-08
JP2018508215A (ja) 2018-03-29
HUE044298T2 (hu) 2019-10-28
PT3265490T (pt) 2019-07-16
CA2978381C (en) 2019-11-05
GB201503742D0 (en) 2015-04-22
FR25C1040I1 (fr) 2025-11-21
ES2732067T3 (es) 2019-11-20
CN107406517A (zh) 2017-11-28
CA2978381A1 (en) 2016-09-09
CN107406517B (zh) 2020-05-12
US11578126B2 (en) 2023-02-14
US20180044417A1 (en) 2018-02-15
AU2016227498A1 (en) 2017-08-31
DK3265490T3 (en) 2020-05-11
AU2016227498B2 (en) 2019-05-02
PL3265490T3 (pl) 2019-10-31
HUS2500036I1 (hu) 2025-09-28
EP3265490A1 (en) 2018-01-10
US20230220077A1 (en) 2023-07-13
JP6574848B2 (ja) 2019-09-11
US20200140544A1 (en) 2020-05-07
US10457730B2 (en) 2019-10-29

Similar Documents

Publication Publication Date Title
TR201909647T4 (tr) Bir cd-19 bağlama alanı içeren kimerik antijen reseptörü (car).
KR102710963B1 (ko) 항b7-h3의 모노클로널 항체 및 그가 세포 치료 중에서의 응용
JP7514746B2 (ja) 細胞
ES3003809T3 (en) Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
RU2685479C2 (ru) Химерный антигенный рецептор
CA3147834A1 (en) Chimeric antigen receptor and immune effector cell expressing chimeric antigen receptor
US20230114854A1 (en) Chimeric antigen receptor targeting b-cell maturation antigen and use thereof
CN111848809A (zh) 靶向Claudin18.2的CAR分子、其修饰的免疫细胞及用途
JP2019510786A (ja) 免疫療法におけるＴＧＦβの阻害
KR20210143097A (ko) Cd22에 특이적인 항체 및 이의 용도
WO2023226921A1 (zh) 靶向bcma-cd19的双特异性嵌合抗原受体及其应用
US20240374727A1 (en) Binding domain
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
US20250144213A1 (en) Circular rna and use thereof
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
EP4620974A1 (en) Anti-afp/hla02 tcr-like antibody and use thereof
WO2023016554A1 (zh) 靶向cd22的抗原结合蛋白及其用途
WO2024082178A1 (zh) 靶向cd19和cd22的双特异性嵌合抗原受体
WO2024230776A1 (zh) Bcmap329g抗体及car-t细胞在治疗多发性骨髓瘤中的应用
CN118510809A (zh) 靶向msln的抗原结合蛋白及其应用
WO2023125766A1 (zh) 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
CN118742319A (zh) 具有抗cd19/抗cd22嵌合抗原受体的基因工程化细胞及其用途
HK1242341B (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
HK1242341A1 (en) Chimeric antigen receptor (car) comprising a cd19-binding domain